Jaideep Behari, MD, PhD, AGAF

The panelist explored the following critical questions: What systems-level strategies can improve coverage readiness for new metabolic dysfunction-associated steatohepatitis (MASH) treatments? What system-wide transformations are necessary to sustain scalable, multidisciplinary MASH care? What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions: What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Welcome back to another AJMC Insights series. In this episode titled, 'The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care', Dr. Jaideep Behari led the conversation about the following questions: The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Panelists discuss how defining and tracking meaningful real-world outcomes ensures accountability and value in MASH management.

Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.

Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH patients.

Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.

Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.

Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.

Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.

Panelists discuss how structured, multidisciplinary screening efforts can catch MASH earlier and prevent progression.

Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention.